Testing a new drug combo for tough rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old
- You have rheumatoid arthritis that is not getting better with standard treatments
- You have tried at least two other advanced medications (biologics or targeted drugs) and they did not work well
- You are willing to take both Telitacicept and Tofacitinib as the trial prescribes
- You do not have severe heart, liver, or lung disease, cancer, or another autoimmune condition
- You are not pregnant, breastfeeding, and will use birth control during the study if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
This study tests whether combining two medicines—methotrexate and tofacitinib—works better for people with a specific type of rheumatoid arthritis. It may be a good fit if you have moderate to severe arthritis, have had a joint biopsy that shows a certain cell pattern, and haven't used similar treatments before.
This trial studies advanced medicines for rheumatoid arthritis (RA) in people whose RA is still active despite several standard treatments. It may help by testing whether a different advanced option can better control symptoms and joint inflammation.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
This study compares two treatment approaches for people with active rheumatoid arthritis who also have heart disease risk factors. It tests whether a newer drug called tofacitinib, combined with cholesterol medication, can better protect the heart than traditional TNF-inhibitor treatments.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
Hear when a new Telitacicept trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.